

A Message to Patients from CEO Keita Mori
regarding Topline Analytical Results of Clinical Trial
Announced on January 29, 2019

Many patients are contacting us concerning analytical results announced on January 29, 2019 regarding a Phase 2b clinical trial of regenerative cell medicine SB623. This trial was conducted in the US for the indication of chronic motor deficit from ischemic stroke. I would once again like to inform you of these analytical results and what they mean moving forward.

SanBio has explored the possibilities of regeneration of damaged nerve cells in the brain through regenerative medicine since its founding 18 years ago. We understand the enormous expectations that patients with chronic motor deficit from ischemic stroke and their families had for SB623.

Precisely because we understand these expectations, we feel a vexing sense of regret that SB623 did not show adequate efficacy in the treatment of chronic motor deficit from ischemic stroke in the Phase 2b clinical trial and that we could not fulfill the hopes of the patients. Of course, this does not mean that I have given up in my pursuit of developing a treatment for chronic motor deficit from ischemic stroke.

The results of the Phase 2b clinical trial indicated that, although SB623 did not meet the primary endpoint, no safety issues were observed. Moving forward, we will conduct a detailed analysis of trial data, promptly investigate and elucidate the reasons that SB623 did not meet the primary endpoint, and reexamine our development plan with our partner, Sumitomo Dainippon Pharma Co., Ltd.

SB623 achieved the primary endpoint for the treatment of chronic motor deficit from traumatic brain injury (TBI) in a global Phase 2 clinical trial conducted in the US and Japan, and we aim to conduct development in accordance with our initial plan in order to achieve an early launch in Japan and worldwide.



All of us at SanBio remain committed to the continuous development of SB623 so that we can deliver new treatments to eagerly anticipating patients as soon as possible.

Keita Mori
CEO
SanBio Co., Ltd.